Research
Molecular
Resmetirom is the first drug approved for MASLD, demonstrating histological efficacy in addressing both steatohepatitis and fibrosis.
Practitioners can consider resmetirom as a treatment option for MASLD.
StrongSupportsmedium confidence
In 2024, the Food and Drug Administration approved resmetirom as the first drug for MASLD, following its demonstrated histological efficacy in addressing both steatohepatitis and fibrosis in a large Phase III trial.
Why this rating
Based on the mention of a large Phase III trial.
Source
The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions
Maria Zasadzińska et al. · Journal of Diabetology · 2025
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →